Streetbeat News

MODD

Modular Medical, Inc.

https://www.modular-medical.com

Industry

Medical - Devices

Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.

Open

2.10

Mkt cap

72M

Volume

115K

High

2.14

P/E Ratio

-3.04

52-wk high

2.65

Low

2.05

Div yield

N/A

52-wk low

1.00

Modular Medical, Inc. has announced the pricing of an $8.2 million public offering, involving 5,450,573 shares of its common stock. The offering is led by existing institutional investors, including Manchester Explorer, L.P.

Portfolio Pulse from

November 22, 2024 | 2:30 am

Modular Medical has announced the issuance of a U.S. patent for key features of its core pumping technology in the FDA-cleared MODD1 insulin delivery product. This patent strengthens the company's intellectual property portfolio.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:08 pm

Modular Medical, Inc. (NASDAQ:MODD) has finalized the protocol for a proof-of-concept study using its MODD1 pump platform for personalized GLP-1 metabolic therapy. The study will begin in October 2024, with results expected in November 2024.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 12:16 pm

Modular Medical, Inc. (NASDAQ:MODD) shares rose after receiving FDA clearance to market its MODD1 pump in the U.S. The pump, aimed at making diabetes technology more accessible, is expected to be available in early 2025. Despite initial gains, the stock has since retracted some of its increase.

Portfolio Pulse from Erica Kollmann

September 05, 2024 | 4:11 pm

Modular Medical shares are rising following the announcement of a conference call to discuss FDA clearance of its MODD1 pump and future plans.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:02 pm

Modular Medical, Inc. (NASDAQ:MODD) announced FDA clearance for its MODD1 insulin pump and will host a conference call to discuss next steps and milestones.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 3:56 pm

Modular Medical, Inc. (NASDAQ:MODD) shares surged 29.1% in pre-market trading following FDA clearance of its MODD1 insulin pump. Other notable pre-market movers include Eastside Distilling, Inc. (NASDAQ:EAST) with a 177.2% gain due to a merger announcement, and C3.ai, Inc. (NYSE:AI) which fell 18.7% after releasing first-quarter results.

Portfolio Pulse from Avi Kapoor

September 05, 2024 | 9:33 am

The trading halt status was updated at 5:00 PM ET, indicating a resumption of quotations. This update may involve MODD, suggesting potential developments or news related to the company.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 9:00 pm

Modular Medical has received FDA clearance for its MODD1 insulin pump, a patch pump designed for adults with Type 1 and Type 2 diabetes. The device aims to be simpler and more affordable, targeting underserved communities. Commercial availability is expected in early 2025.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 8:40 pm

Trading for MODD was halted at 4:16:26 p.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 8:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.